Abstract

Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies.

Details

Title
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Author
Han, Jieun 1 ; Lim, Jaesung 2 ; Wang, Chi-Pin James 2 ; Han, Jun-Hyeok 3 ; Shin, Ha Eun 4 ; Kim, Se-Na 5 ; Jeong, Dooyong 6 ; Lee, Sang Hwi 6 ; Chun, Bok-Hwan 6 ; Park, Chun Gwon 7 ; Park, Wooram 1   VIAFID ORCID Logo 

1  Sungkyunkwan University, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); Sungkyunkwan University, Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
2  SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Department of Biomedical Engineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); SKKU Institute for Convergence, Sungkyunkwan University, Department of Intelligent Precision Healthcare Convergence, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
3  Sungkyunkwan University, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); SKKU Institute for Convergence, Sungkyunkwan University, Department of Intelligent Precision Healthcare Convergence, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
4  Sungkyunkwan University, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
5  MediArk, Cheongju, Republic of Korea (GRID:grid.264381.a) 
6  R&D center of HLB Pharmaceutical Co., Ltd., Hwaseong, Republic of Korea (GRID:grid.264381.a) 
7  SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Department of Biomedical Engineering, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); SKKU Institute for Convergence, Sungkyunkwan University, Department of Intelligent Precision Healthcare Convergence, Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X); Sungkyunkwan University, Biomedical Institute for Convergence at SKKU (BICS), Suwon, Republic of Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X) 
Pages
36
Publication year
2023
Publication date
Dec 2023
Publisher
Springer Nature B.V.
e-ISSN
21965404
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s40580-023-00385-3
ProQuest document ID
2890355052
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.